Answers are grounded in this paper and cite their sources.
sNfL can be considered a prognostic biomarker of future long-term disability progression in patients with progressive MS. These data expand the little knowledge existing on the role of sNfL as long-term prognostic biomarker in patients with progressive MS.
No takes yet. Share an insight, caveat, or question.
Comabella et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: